AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients
Shots:
- The P-III (SUPERNOVA) study investigates the safety & efficacy of sipavibart (300mg, IM, 2nd dose post 6mos. of initial dose) vs control (tixagevimab/cilgavimab or PBO) to prevent COVID-19 in immunocompromised patients (n=3,335)
- The study reached both the dual 1EPs incl. relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and relative risk reduction of infections caused by SARS-CoV-2 variants without F456L mutation
- The drug was well-tolerated with balanced AEs between the sipavibart & control arm. Detailed findings will be highlighted at the upcoming medical conference. AstraZeneca is planning approval pathways with regulatory authorities
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports Data from the P-III (ECHO) Study of Calquence Combination Regimen for Mantle Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
